# Soleno Therapeutics (SLNO) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/SLNO
## Company Profile
- Ticker: SLNO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS, Rare Disease
## Stock Data
- Close: 53.01 USD
- Market cap: 2762888992.47 USD
- Last updated: 2026-05-15
## Business Overview
### Prader-Willi Syndrome Focus
Soleno Therapeutics develops and commercializes therapies for rare diseases. Its initial franchise addresses hyperphagia, the persistent and potentially life-threatening hunger associated with Prader-Willi syndrome.
### VYKAT XR
VYKAT XR is a once-daily extended-release formulation of diazoxide choline approved in the United States for hyperphagia in adults and children age four and older with Prader-Willi syndrome. It is the company’s first commercial product.
### International Expansion
Soleno has begun building a commercial patient and prescriber base in the United States and has submitted a European marketing application. The company plans to use the U.S. launch infrastructure and disease-community relationships to support expansion into additional territories.
## Why The Stock Is Moving

Current closing-price context is not available for SLNO.

## Future Catalysts

- Soleno’s catalysts are DCCR in Prader-Willi syndrome and the next regulatory / commercialization steps around that program. The stock is still driven by whether the rare-disease opportunity can keep advancing.

## Recent News
- 2026-02-26 13:00 EST — [Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer](https://biopharmsignal.com/news/SLNO/soleno-therapeutics-announces-retirement-of-james-mackaness-and-appointment-of-j-e189fa61) — Source: Soleno Therapeutics
- 2026-02-25 21:01 EST — [Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR](https://biopharmsignal.com/news/SLNO/soleno-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results--3aca491a) — Source: Soleno Therapeutics
- 2026-02-11 13:00 EST — [Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET](https://biopharmsignal.com/news/SLNO/soleno-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-result-f5b4af5a) — Source: Soleno Therapeutics
- 2026-01-29 13:00 EST — [Soleno Therapeutics to Participate in Upcoming Conferences](https://biopharmsignal.com/news/SLNO/soleno-therapeutics-to-participate-in-upcoming-conferences-47ed2b8d) — Source: Soleno Therapeutics
- 2026-01-12 12:00 EST — [Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results](https://biopharmsignal.com/news/SLNO/soleno-therapeutics-announces-select-preliminary-fourth-quarter-and-full-year-20-b38ae0a1) — Source: Soleno Therapeutics